Edition:
United States

GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

243JPY
8:53pm EST
Change (% chg)

¥6 (+2.53%)
Prev Close
¥237
Open
¥236
Day's High
¥245
Day's Low
¥234
Volume
463,000
Avg. Vol
1,409,929
52-wk High
¥395
52-wk Low
¥117

2160.T

Chart for 2160.T

About

GNI Group Ltd. is a Japan-based company engaged in the drug discovery activities that utilize biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The... (more)
No analyst recommendations are available for 2160.T.

Overall

Beta: 1.45
Market Cap(Mil.): ¥25,541.56
Shares Outstanding(Mil.): 114.02
Dividend: --
Yield (%): --

Financials

  2160.T Industry Sector
P/E (TTM): -- 45.92 30.50
EPS (TTM): -7.63 -- --
ROI: -21.29 -1.27 14.84
ROE: -23.93 -1.00 16.26

BRIEF-GNI Group gets approval for clinical trial in China for drug of diabetic nephropathy

* Says it received approval from China Food and Drug Administration for a pulmonary fibrosis treatment drug's effect on diabetic nephropathy

Aug 17 2016

BRIEF-GNI Group unit gets manufacture and marketing approval of Etuary in China

* Says its unit Beijing Continent Pharmaceuticals Co., Ltd. obtained the manufacture and marketing approval of Etuary for the treatment of idiopathic pulmonary fibrosis in China

Aug 03 2016

Earnings vs. Estimates